Home LiteratureArticle Details
PMID: 22718858 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment.

Clinical cancer research : an official journal of the American Association for Cancer Research ·Vol. 18 ·No. 18 ·2012-09-15 ·Pages 4877-82

Lu T, Gabrilovich DI

Abstract

Tumor-associated myeloid cells are the major type of inflammatory cells involved in the regulation of antitumor immune responses. One key characteristic of these cells is the generation of reactive oxygen (ROS) and reactive nitrogen species (RNS) in the tumor microenvironment. Recent studies have shown the important role of ROS and RNS, especially peroxynitrite, in immune suppression in cancer. ROS and RNS are involved in induction of antigen-specific T-cell tolerance, inhibition of T-cell migration to the tumor site, and tumor cell evasion of recognition by cytotoxic T cells. In preclinical settings, a number of potential therapeutic agents showed activity in blocking ROS/RNS in cancer and in improving the efficacy of cancer immune therapy. A better understanding of ROS/RNS-associated pathways in myeloid cells will help to identify more specific and direct targets to facilitate the development of more effective immune therapy for cancer.

MeSH Terms
Humans Myeloid Cells/immunology,metabolism Neoplasms/immunology,metabolism,pathology Peroxynitrous Acid/metabolism Reactive Nitrogen Species/metabolism Signal Transduction Translational Research, Biomedical Tumor Microenvironment/immunology
Chemicals
Reactive Nitrogen Species Peroxynitrous Acid
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Lu Tangying
H. Lee Moffitt CancerCenter, MRC 2067, 12902 Magnolia Drive, Tampa, FL 33612, USA.
Gabrilovich Dmitry I
References (56)
56 references, click to expand
  1. Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells.
    Cancer Res. 2007 Dec 1;67(23):11447-54 PMID: 18056473
  2. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function.
    J Exp Med. 2006 Nov 27;203(12):2691-702 PMID: 17101732
  3. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.
    Clin Cancer Res. 2009 Mar 15;15(6):2148-57 PMID: 19276286
  4. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells.
    J Immunol. 2009 May 1;182(9):5693-701 PMID: 19380816
  5. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma.
    J Exp Med. 2005 Oct 3;202(7):931-9 PMID: 16186186
  6. Cutting edge: MHC class II-restricted peptides containing the inflammation-associated marker 3-nitrotyrosine evade central tolerance and elicit a robust cell-mediated immune response.
    J Immunol. 2003 Jul 15;171(2):528-32 PMID: 12847213
  7. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.
    Nat Immunol. 2010 Oct;11(10):889-96 PMID: 20856220
  8. Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3.
    Eur J Immunol. 1994 Dec;24(12):3233-6 PMID: 7805752
  9. Indoleamine 2,3-dioxygenase and tumor-induced tolerance.
    J Clin Invest. 2007 May;117(5):1147-54 PMID: 17476344
  10. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties.
    J Leukoc Biol. 2011 Feb;89(2):311-7 PMID: 21106641
  11. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.
    Cancer Res. 2007 May 1;67(9):4507-13 PMID: 17483367
  12. Hallmarks of cancer: the next generation.
    Cell. 2011 Mar 4;144(5):646-74 PMID: 21376230
  13. Tumor iNOS predicts poor survival for stage III melanoma patients.
    Int J Cancer. 2006 Aug 15;119(4):861-6 PMID: 16557582
  14. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.
    Nat Med. 2007 Jul;13(7):828-35 PMID: 17603493
  15. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis.
    Clin Cancer Res. 2006 Feb 15;12(4):1201-7 PMID: 16489074
  16. Neutrophil kinetics in health and disease.
    Trends Immunol. 2010 Aug;31(8):318-24 PMID: 20620114
  17. Adoptive immunotherapy for cancer: harnessing the T cell response.
    Nat Rev Immunol. 2012 Mar 22;12(4):269-81 PMID: 22437939
  18. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein.
    J Exp Med. 2008 Sep 29;205(10):2235-49 PMID: 18809714
  19. Immunotherapy earns its spot in the ranks of cancer therapy.
    J Exp Med. 2012 Feb 13;209(2):201-9 PMID: 22330682
  20. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival.
    Clin Cancer Res. 2000 Dec;6(12):4768-75 PMID: 11156233
  21. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.
    Cancer Res. 2001 Jun 15;61(12):4756-60 PMID: 11406548
  22. Myeloid-derived suppressor cells as regulators of the immune system.
    Nat Rev Immunol. 2009 Mar;9(3):162-74 PMID: 19197294
  23. Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex.
    J Exp Med. 1995 May 1;181(5):1881-6 PMID: 7722462
  24. Conversion of tyrosine to the inflammation-associated analog 3'-nitrotyrosine at either TCR- or MHC-contact positions can profoundly affect recognition of the MHC class I-restricted epitope of lymphocytic choriomeningitis virus glycoprotein 33 by CD8 T cells.
    J Immunol. 2008 May 1;180(9):5956-62 PMID: 18424715
  25. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.
    J Exp Med. 2011 Sep 26;208(10):1949-62 PMID: 21930770
  26. Ultrastructural and chromosomal studies on manganese superoxide dismutase in malignant mesothelioma.
    Am J Respir Cell Mol Biol. 2004 Aug;31(2):147-53 PMID: 15039138
  27. Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils.
    Antioxid Redox Signal. 2007 Nov;9(11):1963-70 PMID: 17822364
  28. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers.
    J Exp Med. 2005 Apr 18;201(8):1257-68 PMID: 15824085
  29. Inhibitory B7-family molecules in the tumour microenvironment.
    Nat Rev Immunol. 2008 Jun;8(6):467-77 PMID: 18500231
  30. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.
    Blood. 2011 Aug 25;118(8):2254-65 PMID: 21734236
  31. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells.
    J Immunol. 2010 Mar 15;184(6):3106-16 PMID: 20142361
  32. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment.
    J Exp Med. 2010 Oct 25;207(11):2439-53 PMID: 20876310
  33. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity.
    Eur J Immunol. 2010 Nov;40(11):2969-75 PMID: 21061430
  34. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.
    Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4185-90 PMID: 15753302
  35. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.
    J Immunol. 2003 Jan 1;170(1):270-8 PMID: 12496409
  36. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
    Clin Cancer Res. 2002 Oct;8(10):3137-45 PMID: 12374681
  37. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.
    BMC Cancer. 2010 Aug 30;10:464 PMID: 20804550
  38. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients.
    Cancer Res. 2006 Sep 15;66(18):9299-307 PMID: 16982775
  39. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice.
    J Leukoc Biol. 2012 Jan;91(1):167-81 PMID: 21954284
  40. Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes.
    Cell Immunol. 1998 Dec 15;190(2):141-55 PMID: 9878115
  41. Myeloid-derived suppressor cell heterogeneity and subset definition.
    Curr Opin Immunol. 2010 Apr;22(2):238-44 PMID: 20171075
  42. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN.
    Cancer Cell. 2009 Sep 8;16(3):183-94 PMID: 19732719
  43. Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells.
    Cancer Res. 2003 Dec 15;63(24):8670-3 PMID: 14695179
  44. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
    Cancer Res. 2009 Mar 15;69(6):2506-13 PMID: 19244102
  45. Immunosuppressive strategies that are mediated by tumor cells.
    Annu Rev Immunol. 2007;25:267-96 PMID: 17134371
  46. Cancer immunotherapy comes of age.
    Nature. 2011 Dec 21;480(7378):480-9 PMID: 22193102
  47. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy.
    Clin Cancer Res. 1996 Aug;2(8):1263-74 PMID: 9816296
  48. Selective nitration of histone tyrosine residues in vivo in mutatect tumors.
    J Biol Chem. 2002 Feb 1;277(5):3614-21 PMID: 11723112
  49. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer.
    Clin Cancer Res. 2010 Mar 15;16(6):1812-23 PMID: 20215551
  50. Subsets, expansion and activation of myeloid-derived suppressor cells.
    Med Microbiol Immunol. 2010 Aug;199(3):273-81 PMID: 20376485
  51. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice.
    J Clin Invest. 2011 Oct;121(10):4015-29 PMID: 21911941
  52. Association of increased immunostaining for inducible nitric oxide synthase and nitrotyrosine with fibroblast growth factor transformation in pancreatic cancer.
    Arch Surg. 1999 Mar;134(3):245-51 PMID: 10088562
  53. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses.
    Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13119-24 PMID: 8917554
  54. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer.
    Nat Rev Cancer. 2007 May;7(5):357-69 PMID: 17446857
  55. Nitroaspirins and morpholinosydnonimine but not aspirin inhibit the formation of superoxide and the expression of gp91phox induced by endotoxin and cytokines in pig pulmonary artery vascular smooth muscle cells and endothelial cells.
    Circulation. 2004 Aug 31;110(9):1140-7 PMID: 15326075
  56. Coordinated regulation of myeloid cells by tumours.
    Nat Rev Immunol. 2012 Mar 22;12(4):253-68 PMID: 22437938
Article Info
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Abbr.
Clin Cancer Res
ISSN
1557-3265
DOI
10.1158/1078-0432.CCR-11-2939
Published
2012-09-15
Epub
2012-00-19
Pages
4877-82
Language
English
Region
United States
NLM ID
9502500
PMCID
PMC3445728
Subset
IM
Grants
NCI NIH HHS · R01 CA084488 · United States
NCI NIH HHS · R01 CA100062 · United States
NCI NIH HHS · R21CA155733 · United States
NCI NIH HHS · R01CA127574 · United States
External Links
PubMed source DOI: 10.1158/1078-0432.CCR-11-2939 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2